Details of the Drug

General Information of Drug (ID: DM5PCS7)

Drug Name

Bupropion

Synonyms

bupropion; Amfebutamone; 34911-55-2; Amfebutamon; 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one; amfebutamonum; Amfebutamona; (+-)-Bupropion; Wellbatrin; Bupropion [INN:BAN]; 34841-39-9; Elontril; Amfebutamonum [INN-Latin]; Zyban; Amfebutamona [INN-Spanish]; Bupropion SR; AMFEBUTAMONE HCl; alpha-(tert-butylamino)-m-chloropropiophenone; CHEMBL894; BRN 2101062; (+-)-1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone; CHEBI:3219; SNPPWIUOZRMYNY-UHFFFAOYSA-N; 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]propan-1-one; Amfebutamon; Amfebutamonum; Elont; Bupropion Hcl; Bupropion hydrocloride; Bupropion (INN); Bupropion (Old RN); Bupropion (USAN); Alpha-(tert-Butylamino)-m-chloropropiophenone; Alpha-(tert-butylamino)-m-chloropropiophenone; (-)-2-(tert-Butylamino)-3'-chloropropiophenone; (-)-2-(tert-Butylamino)-3'-chlorpropiophenon; 1-Propanone; 2-(Tert-Butylamino)-3'-chloropropiophenone

Indication

Disease Entry	ICD 11	Status	REF
Smoking dependence	6C4A.2	Approved	[1]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

239.74

Topological Polar Surface Area (xlogp)

3.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 2 h [2]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Elimination: 0.5% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 24 hours [4]
Metabolism: The drug is metabolized via the hydroxylation of the tert-butyl group of bupropion [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 31.28291 micromolar/kg/day [6]
Water Solubility: The ability of drug to dissolve in water is measured as 312 mg/mL [3]

Chemical Identifiers

Formula: C13H18ClNO
IUPAC Name: 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one
Canonical SMILES: CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C
InChI: InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3
InChIKey: SNPPWIUOZRMYNY-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 444
ChEBI ID: CHEBI:3219
CAS Number: 34911-55-2
DrugBank ID: DB01156
TTD ID: D0X4ZR
VARIDT ID: DR00836
INTEDE ID: DR0247
ACDINA ID: D00083

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Norepinephrine transporter (NET)	TTAWNKZ	SC6A2_HUMAN	Inhibitor	[7]
Serotonin transporter (SERT)	TT3ROYC	SC6A4_HUMAN	Inhibitor	[7]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[8]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2E1 (CYP2E1)	DEVDYN7	CP2E1_HUMAN	Substrate	[10]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[11]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[12]
Cytochrome P450 2B6 (CYP2B6)_{Main DME}	DEPKLMQ	CP2B6_HUMAN	Substrate	[13]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Smoking dependence

ICD Disease Classification

6C4A.2

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Serotonin transporter (SERT)	DTT	SLC6A4	8.76E-01	7.18E-05	6.19E-04
P-glycoprotein 1 (ABCB1)	DTP	P-GP	6.54E-01	1.95E-01	4.04E-01
Breast cancer resistance protein (ABCG2)	DTP	BCRP	9.26E-01	-9.37E-02	-1.15E-01
Cytochrome P450 2E1 (CYP2E1)	DME	CYP2E1	9.45E-02	-1.86E-01	-9.83E-01
Cytochrome P450 2B6 (CYP2B6)	DME	CYP2B6	4.32E-01	4.39E-02	4.30E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	8.70E-01	2.98E-02	1.22E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	2.35E-01	2.78E-02	2.09E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Bupropion (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Bupropion and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[77]
Methylene blue	DMJAPE7	Major	Additive serotonergic effects by the combination of Bupropion and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[78]
Arn-509	DMT81LZ	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Arn-509.	Acute myeloid leukaemia [2A60]	[79]
Oliceridine	DM6MDCF	Major	Decreased metabolism of Bupropion caused by Oliceridine mediated inhibition of CYP450 enzyme.	Acute pain [MG31]	[80]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Bupropion and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[81]
Aminophylline	DML2NIB	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Aminophylline.	Asthma [CA23]	[79]
Ofloxacin	DM0VQN3	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[79]
Sparfloxacin	DMB4HCT	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[79]
Imipenem	DMI9FBP	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Imipenem.	Bacterial infection [1A00-1C4Z]	[82]
ABT-492	DMJFD2I	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and ABT-492.	Bacterial infection [1A00-1C4Z]	[79]
Cariprazine	DMJYDVK	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Cariprazine.	Bipolar disorder [6A60]	[79]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Bupropion and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[83]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Bupropion caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[84]
Thiotepa	DMIZKOP	Moderate	Decreased metabolism of Bupropion caused by Thiotepa mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[85]
Corticotropin	DMP9TWZ	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Corticotropin.	Chronic kidney disease [GB61]	[79]
Dihydrocodeine	DMB0FWL	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Dihydrocodeine.	Chronic pain [MG30]	[82]
Levomilnacipran	DMV26S8	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Levomilnacipran.	Chronic pain [MG30]	[79]
Oxtriphylline	DMLHSE3	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Oxtriphylline.	Cough [MD12]	[79]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Bupropion caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[86]
Vilazodone	DM4LECQ	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Vilazodone.	Depression [6A70-6A7Z]	[79]
Vortioxetine	DM6F1PU	Major	Decreased metabolism of Bupropion caused by Vortioxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[87]
Isocarboxazid	DMAF1NB	Major	Additive hypertensive effects by the combination of Bupropion and Isocarboxazid.	Depression [6A70-6A7Z]	[88]
Milnacipran	DMBFE74	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Milnacipran.	Depression [6A70-6A7Z]	[79]
Desvenlafaxine	DMHD4PE	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Desvenlafaxine.	Depression [6A70-6A7Z]	[79]
OPC-34712	DMHG57U	Major	Decreased metabolism of Bupropion caused by OPC-34712 mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[89]
Clomipramine	DMINRKW	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Clomipramine.	Depression [6A70-6A7Z]	[90]
Heroin diacetylmorphine	DMDBWHY	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Heroin diacetylmorphine.	Dissociative neurological symptom disorder [6B60]	[82]
Tetrabenazine	DMYWQ0O	Major	Decreased metabolism of Bupropion caused by Tetrabenazine mediated inhibition of CYP450 enzyme.	Dissociative neurological symptom disorder [6B60]	[91]
Deutetrabenazine	DMUPFLI	Major	Decreased metabolism of Bupropion caused by Deutetrabenazine mediated inhibition of CYP450 enzyme.	Dystonic disorder [8A02]	[92]
Ingrezza	DMVPLNC	Major	Decreased metabolism of Bupropion caused by Ingrezza mediated inhibition of CYP450 enzyme.	Dystonic disorder [8A02]	[93]
Cenobamate	DMGOVHA	Moderate	Increased metabolism of Bupropion caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[94]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Bupropion caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[84]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Bupropion caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[95]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Bupropion and Cannabidiol.	Epileptic encephalopathy [8A62]	[84]
Procarbazine	DMIK367	Major	Additive hypertensive effects by the combination of Bupropion and Procarbazine.	Hodgkin lymphoma [2B30]	[88]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Bupropion and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[96]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Bupropion and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[90]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Bupropion and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[97]
Nebivolol	DM7F1PA	Moderate	Decreased metabolism of Bupropion caused by Nebivolol mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[98]
Pirfenidone	DM6VZFQ	Moderate	Decreased metabolism of Bupropion caused by Pirfenidone mediated inhibition of CYP450 enzyme.	Idiopathic interstitial pneumonitis [CB03]	[84]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Bupropion caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[95]
ITI-007	DMUQ1DO	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and ITI-007.	Insomnia [7A00-7A0Z]	[79]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Bupropion and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[99]
Eluxadoline	DMYZ0P1	Moderate	Decreased metabolism of Bupropion caused by Eluxadoline mediated inhibition of CYP450 enzyme.	Irritable bowel syndrome [DD91]	[100]
Amifampridine	DMK08L3	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Amifampridine.	Lambert-Eaton syndrome [8C62]	[79]
Nelarabine	DMB6VEG	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Nelarabine.	Leukaemia [2A60-2B33]	[79]
Crizotinib	DM4F29C	Moderate	Decreased clearance of Bupropion due to the transporter inhibition by Crizotinib.	Lung cancer [2C25]	[77]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Bupropion caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[84]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Bupropion and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[101]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Bupropion and Idelalisib.	Mature B-cell leukaemia [2A82]	[102]
Blinatumomab	DMGECIJ	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Blinatumomab.	Mature B-cell lymphoma [2A85]	[79]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Bupropion caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[77]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Bupropion and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[103]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Bupropion and Lasmiditan.	Migraine [8A80]	[104]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Bupropion and Flibanserin.	Mood disorder [6A60-6E23]	[105]
Dalfampridine	DMM0PDO	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Dalfampridine.	Multiple sclerosis [8A40]	[79]
Deflazacort	DMV0RNS	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Deflazacort.	Muscular dystrophy [8C70]	[79]
Neostigmine	DM6T2J3	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Neostigmine.	Myasthenia gravis [8C6Y]	[79]
Nilotinib	DM7HXWT	Moderate	Increased metabolism of Bupropion caused by Nilotinib mediated induction of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[77]
Prasugrel	DM7MT6E	Minor	Decreased metabolism of Bupropion caused by Prasugrel mediated inhibition of CYP450 enzyme.	Myocardial infarction [BA41-BA43]	[84]
Dextroamphetamine	DMMIHVP	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Dextroamphetamine.	Narcolepsy [7A20]	[90]
Metoclopramide	DMFA5MY	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Metoclopramide.	Nausea/vomiting [MD90]	[90]
Phendimetrazine	DM6TS1N	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Phendimetrazine.	Obesity [5B80-5B81]	[79]
Lorcaserin	DMG6OYJ	Major	Additive serotonergic effects by the combination of Bupropion and Lorcaserin.	Obesity [5B80-5B81]	[106]
Dexfenfluramine	DMJ7YDS	Major	Decreased metabolism of Bupropion caused by Dexfenfluramine mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[90]
Levomethadyl Acetate	DM06HG5	Major	Additive CNS depression effects by the combination of Bupropion and Levomethadyl Acetate.	Opioid use disorder [6C43]	[105]
Olaparib	DM8QB1D	Moderate	Increased metabolism of Bupropion caused by Olaparib mediated induction of CYP450 enzyme.	Ovarian cancer [2C73]	[77]
Oxymorphone	DM65AGJ	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Oxymorphone.	Pain [MG30-MG3Z]	[79]
Dezocine	DMJDB0Y	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Dezocine.	Pain [MG30-MG3Z]	[79]
Methamphetamine	DMPM4SK	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Methamphetamine.	Pain [MG30-MG3Z]	[95]
Safinamide	DM0YWJC	Major	Additive hypertensive effects by the combination of Bupropion and Safinamide.	Parkinsonism [8A00]	[88]
Rasagiline	DM3WKQ4	Major	Additive hypertensive effects by the combination of Bupropion and Rasagiline.	Parkinsonism [8A00]	[88]
Orphenadrine	DMW542E	Moderate	Decreased metabolism of Bupropion caused by Orphenadrine mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[85]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Bupropion caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[107]
Levomepromazine	DMIKFEL	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Levomepromazine.	Psychotic disorder [6A20-6A25]	[90]
Dexamethasone	DMMWZET	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Dexamethasone.	Rheumatoid arthritis [FA20]	[79]
Quetiapine	DM1N62C	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Quetiapine.	Schizophrenia [6A20]	[79]
Aripiprazole	DM3NUMH	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Aripiprazole.	Schizophrenia [6A20]	[90]
Iloperidone	DM6AUFY	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Iloperidone.	Schizophrenia [6A20]	[90]
Molindone	DMAH70G	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Molindone.	Schizophrenia [6A20]	[79]
Thiothixene	DMDINC4	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Thiothixene.	Schizophrenia [6A20]	[79]
Asenapine	DMSQZE2	Major	Increased risk of lowers seizure threshold by the combination of Bupropion and Asenapine.	Schizophrenia [6A20]	[79]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Bupropion caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[84]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Bupropion and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[84]
Pitolisant	DM8RFNJ	Major	Decreased metabolism of Bupropion caused by Pitolisant mediated inhibition of CYP450 enzyme.	Somnolence [MG42]	[84]
Trimeprazine	DMEMV9D	Major	Decreased metabolism of Bupropion caused by Trimeprazine mediated inhibition of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[95]
Propafenone	DMPIBJK	Moderate	Decreased metabolism of Bupropion caused by Propafenone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[98]
Flecainide	DMSQDLE	Moderate	Decreased metabolism of Bupropion caused by Flecainide mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[98]
-----------


⏷ Show the Full List of 88 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Benzosulfimide	E00076	5143	Flavoring agent
Cysteine hydrochloride	E00318	25150	Antioxidant
D&C red no. 27	E00381	83511	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Fumaric acid	E00420	444972	Acidulant; Antioxidant; Complexing agent; Flavoring agent; Solubilizing agent
Glutamic acid hydrochloride	E00448	2723891	Acidulant
Hydrazine yellow	E00409	164825	Colorant
Hydrochloric acid	E00015	313	Acidulant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Maleic acid	E00418	444266	Acidulant; Buffering agent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Potassium chloride	E00074	4873	Tonicity agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate	E00545	23665634	lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Ammonium chloride	E00321	25517	Acidulant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Citric acid monohydrate	E00271	22230	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Crospovidone	E00626	Not Available	Disintegrant
Dibutyl sebacate	E00160	7986	Plasticizing agent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Glyceryl behenate	E00481	5362585	Binding agent; Coating agent; Flavoring agent; Modified-release agent; Viscosity-controlling agent; lubricant
Glyceryl dibehenate	E00537	22477175	Binding agent; Coating agent; Flavoring agent; Modified-release agent; Viscosity-controlling agent; lubricant
Hydroxypropyl cellulose	E00632	Not Available	Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Lithol rubin BCA	E00607	135423095	Colorant
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 1000	E00647	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate	E00424	516892	Alkalizing agent; Diluent
Soybean lecithin	E00637	Not Available	Other agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
Water	E00035	962	Solvent
Certolake sunset yellow	E00351	61817	Colorant
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
--------------------


⏷ Show the Full List of 55 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Bupropion 150 mg tablet	150 mg	12 HR Extended Release Oral Tablet	Oral
Bupropion 100 mg tablet	100 mg	12 HR Extended Release Tablet	Oral
Bupropion 150 mg tablet	150 mg	12 HR Extended Release Tablet	Oral
Bupropion 200 mg tablet	200 mg	12 HR Extended Release Tablet	Oral
Bupropion 100 mg tablet	100 mg	Oral Tablet	Oral
Bupropion 150 mg tablet	150 mg	Smoking Cessation 12 HR Extended Release Oral Tablet	Oral
Bupropion 200 mg tablet	200 mg	12 HR Extended Release Oral Tablet	Oral
Bupropion 150 mg tablet	150 mg	24 HR Extended Release Oral Tablet	Oral
Bupropion 300 mg tablet	300 mg	24 HR Extended Release Oral Tablet	Oral
Bupropion 450 mg tablet	450 mg	24 HR Extended Release Oral Tablet	Oral
Bupropion 300 mg tablet	300 mg	24 HR Extended Release Tablet	Oral
Bupropion 100 mg tablet	100 mg	12 HR Extended Release Oral Tablet	Oral
Bupropion 75 mg tablet	75 mg	Oral Tablet	Oral
Bupropion Hydrochloride 100mg extended release tablet	100mg	Extended Release Tablet	Oral
Bupropion Hydrochloride 50mg tablet	50mg	Tablet	Oral
Bupropion 150 mg tablet	150 mg	24 HR Extended Release Tablet	Oral
Bupropion 348 mg tablet	348 mg	24 HR Extended Release Oral Tablet	Oral
Bupropion 522 mg tablet	522 mg	24 HR Extended Release Oral Tablet	Oral
Bupropion 174 mg tablet	174 mg	24 HR Extended Release Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Nakamura K, Yokoi T, Inoue K, Shimada N, Ohashi N, Kume T, Kamataki T: CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes. Pharmacogenetics. 1996 Oct;6(5):449-57.
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
8	Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion. Biochem Pharmacol. 2010 Oct 1;80(7):1080-6.
9	Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein. Biol Pharm Bull. 2008 Feb;31(2):231-4.
10	Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos. 2000 Oct;28(10):1222-30.
11	In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation. Biochem Pharmacol. 2017 Jan 1;123:85-96.
12	Product Monograph of Wellbutrin SR(Bupropion Hydrochloride).
13	Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. Basic Clin Pharmacol Toxicol. 2019 Aug;125(2):123-132.
14	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
15	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
16	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
17	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
18	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
19	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
20	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
21	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
22	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
23	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
24	Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
25	Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
26	Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
27	Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
28	A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
29	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
30	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
31	Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
32	Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
33	CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
34	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
35	Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
36	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
37	Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
38	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
39	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
40	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
41	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
42	Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
43	Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
44	Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
45	Drugs that may have potential CYP2B6 interactions.
46	Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
47	Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
48	PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
49	Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
50	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
51	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
52	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
53	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
54	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
55	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
56	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
57	Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
58	Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
59	The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
60	Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
61	Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
62	Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
63	The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
64	Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
65	Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
66	Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
67	Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
68	Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
69	Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
70	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
71	Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
72	Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
73	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
74	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
75	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
76	Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
77	Cerner Multum, Inc. "Australian Product Information.".
78	Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
79	Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
80	Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
81	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
82	Sheehan DV, Welch JB, Fishman SM "A case of bupropion-induced seizure." J Nerv Ment Dis 174 (1986): 496-8. [PMID: 3090199]
83	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
84	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
85	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
86	Cerner Multum, Inc. "Canadian Product Information.".
87	Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
88	De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5. [PMID: 4379192]
89	Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
90	Canadian Pharmacists Association.
91	Product Information. Xenazine (tetrabenazine). Prestwick Pharmaceuticals Inc, Washington DC, VA.
92	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
93	Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
94	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
95	James WA, Lippmann S "Bupropion: overview and prescribing guidelines in depression." South Med J 84 (1991): 222-4. [PMID: 1899294]
96	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
97	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
98	Dufresne RL, Weber SS, Becker RE "Bupropion hydrochloride." Drug Intell Clin Pharm 18 (1984): 957-64. [PMID: 6439541]
99	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
100	Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
101	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
102	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
103	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
104	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
105	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
106	Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
107	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.